Connect with us

Coronavirus Outbreak

No Extra Blood Clot Risk After Second Dose Of AstraZeneca Covid Vaccine: Study

The research, published in The Lancet shows that the rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of the COVID-19 vaccine of AstraZeneca are comparable to those among unvaccinated population

No Extra Blood Clot Risk After Second Dose Of AstraZeneca Covid Vaccine: Study
Highlights
  • AstraZeneca vaccine is known as Covishield in India
  • AstraZeneca vaccine uses a weakened version of a common cold virus
  • AstraZeneca vaccine has been granted emergency use in over 80 countries

London: The AstraZeneca COVID-19 vaccine is associated with a small risk of rare blood clots after the first dose, and no extra risk after the second shot, according to a study led and funded by the British-Swedish drugmaker. The research, published in The Lancet on Tuesday (July 27), shows that the rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of the vaccine are comparable to those among unvaccinated population.

Also Read:  Understanding The Pace Of India’s Coronavirus Vaccination Drive

TTS is a very rare syndrome which occurs when a person has blood clots (thrombosis) as well as low platelet counts (thrombocytopenia). It is also referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). Rare cases of TTS have been reported after immunisation with the AstraZeneca vaccine, known as Covishield in India, which led to several countries restricting or stopping the use of the preventive.

The authors demonstrated that the estimated rate of TTS following a second dose of AstraZeneca was 2.3 per million vaccinees, comparable to the rate observed in an unvaccinated population. The rate was 8.1 per million vaccinees after the first dose, they said.

The analysis was conducted using AstraZeneca’s global safety database, which captures all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide.

Reported cases of TTS globally were included up to the cut-off date of April 30 this year occurring within 14 days of administration of the first or second dose of AstraZeneca vaccine. The results are in line with recent reports in the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Report, the UK system for collecting and monitoring information on safety concerns, which also show low rates of TTS after a second dose, AstraZeneca said.

No specific risk factors or definitive cause for TTS following COVID-19 vaccination have been identified and AstraZeneca continues to perform and support ongoing investigations of potential mechanisms. Furthermore, these very rare events can be avoided when symptoms are identified and treated appropriately, the company said in a statement.

Co-developed by the University of Oxford, the AstraZeneca vaccine is based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees. The preventive contains the genetic material of the SARS-CoV-2 virus spike protein, which the virus uses to enter and infect the human cells. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. According to its manufacturers, the AstraZeneca vaccine has been granted emergency use in more than 80 countries across six continents.

Also Read: Will Third Wave Be Severe? When Can Children Get COVID-19 Vaccine? AIIMS Chief Dr Randeep Guleria Tells NDTV

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

22,95,44,435Cases
19,20,52,504Active
3,27,83,741Recovered
47,08,190Deaths
Coronavirus has spread to 195 countries. The total confirmed cases worldwide are 22,95,44,435 and 47,08,190 have died; 19,20,52,504 are active cases and 3,27,83,741 have recovered as on September 22, 2021 at 3:49 am.

India

3,35,31,498 26,964Cases
3,01,9897,586Active
3,27,83,741 34,167Recovered
4,45,768 383Deaths
In India, there are 3,35,31,498 confirmed cases including 4,45,768 deaths. The number of active cases is 3,01,989 and 3,27,83,741 have recovered as on September 22, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

65,27,629 3,131

44,269 960

63,44,744 4,021

1,38,616 70

Kerala

45,39,926 15,768

1,61,765 5,813

43,54,264 21,367

23,897 214

Karnataka

29,69,361 818

13,769 617

29,17,944 1,414

37,648 21

Tamil Nadu

26,48,688 1,647

16,993 9

25,96,316 1,619

35,379 19

Andhra Pradesh

20,40,708 1,179

13,905 483

20,12,714 1,651

14,089 11

Uttar Pradesh

17,09,693 13

194 0

16,86,612 13

22,887

West Bengal

15,62,710 537

7,741 69

15,36,291 592

18,678 14

Delhi

14,38,556 39

400 21

14,13,071 18

25,085

Odisha

10,21,216 462

4,844 103

10,08,226 560

8,146 5

Chhattisgarh

10,05,120 26

297 0

9,91,260 26

13,563

Rajasthan

9,54,275 12

99 8

9,45,222 4

8,954

Gujarat

8,25,751 14

133 0

8,15,536 14

10,082

Madhya Pradesh

7,92,410 8

90 6

7,81,803 14

10,517

Haryana

7,70,754 8

328 12

7,60,618 20

9,808

Bihar

7,25,907 6

60 9

7,16,188 15

9,659

Telangana

6,63,906 244

4,938 53

6,55,061 296

3,907 1

Punjab

6,01,359 36

304 3

5,84,554 37

16,501 2

Assam

5,98,864 441

5,081 97

5,87,970 338

5,813 6

Jharkhand

3,48,139 14

65 10

3,42,941 4

5,133

Uttarakhand

3,43,405 12

249 18

3,35,765 29

7,391 1

Jammu And Kashmir

3,28,214 145

1,450 11

3,22,345 154

4,419 2

Himachal Pradesh

2,17,403 263

1,715 99

2,12,033 162

3,655 2

Goa

1,75,690 107

886 76

1,71,507 29

3,297 2

Puducherry

1,25,618 101

922 55

1,22,864 46

1,832

Manipur

1,18,870 197

2,174 9

1,14,861 203

1,835 3

Tripura

83,956 51

353 7

82,794 44

809

Mizoram

82,815 1,355

15,363 223

67,184 1,127

268 5

Meghalaya

79,817 150

1,878 18

76,558 167

1,381 1

Chandigarh

65,195 7

44 3

64,333 4

818

Arunachal Pradesh

54,190 64

413 3

53,504 60

273 1

Sikkim

31,014 43

627 27

30,007 70

380

Nagaland

30,959 52

470 3

29,832 46

657 3

Ladakh

20,743 6

144 6

20,392

207

Dadra And Nagar Haveli

10,670

0 0

10,666

4

Lakshadweep

10,360 1

9 1

10,300

51

Andaman And Nicobar Islands

7,607 7

17 4

7,461 3

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Leaving No One Behind

Mental Health

Environment

Join Us